| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
|
Medicine details |
|
| Medicine name | peginterferon alfa-2a (Pegasys®) |
| Formulation | 90 micrograms, 135 micrograms, 180 micrograms solution for injection |
| Reference number | 1974 |
| Indication | In combination with ribavirin for the treatment of chronic hepatitis C in treatment-naive children and adolescents five years of age and older who are positive for serum hepatitis-C-virus ribonucleic acid (HCV-RNA). When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis |
| Company | Roche Products Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/04/2013 |
| NICE guidance | |